Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000921895-26-000457·BIOTECHNOLOGY VALUE FUND L P
Schedule 13G ownership disclosure
Cullinan Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 230031106
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- BIOTECHNOLOGY VALUE FUND L P
Shares: 3,302,376.00 · Class: 5.6%
- BVF I GP LLC
Shares: 3,302,376.00 · Class: 5.6%
- BIOTECHNOLOGY VALUE FUND II LP
Shares: 2,271,662.00 · Class: 3.8%
- BVF II GP LLC
Shares: 2,271,662.00 · Class: 3.8%
- Biotechnology Value Trading Fund OS LP
Shares: 224,641.00 · Class: 0.4%
- BVF Partners OS Ltd.
Shares: 224,641.00 · Class: 0.4%
- BVF GP HOLDINGS LLC
Shares: 5,574,038.00 · Class: 9.4%
- BVF PARTNERS L P/IL
Shares: 5,918,481.00 · Class: 9.99%
- BVF INC/IL
Shares: 5,918,481.00 · Class: 9.99%
- LAMPERT MARK N
Shares: 5,918,481.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000921895-26-000457
- Form type
- SCHEDULE 13G/A
- Filer
- BIOTECHNOLOGY VALUE FUND L P
- CIK
- CIK 918923
- Filed
- Feb 17, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership